1
|
Haasjes C, Vu THK, Beenakker JM. Patient-specific mapping of fundus photographs to three-dimensional ocular imaging. Med Phys 2025; 52:2330-2339. [PMID: 39666442 PMCID: PMC11972038 DOI: 10.1002/mp.17576] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2024] [Revised: 11/23/2024] [Accepted: 12/02/2024] [Indexed: 12/14/2024] Open
Abstract
BACKGROUND Ocular proton beam therapy (OPT) planning would benefit from an accurate incorporation of fundus photographs, as various intra-ocular structures, such as the fovea, are not visible on conventional modalities such as Magnetic Resonance Imaging (MRI). However, the use of fundus photographs in OPT is limited, as the eye's optics induce a nonuniform patient-specific deformation to the images. PURPOSE To develop a method to accurately map fundus photographs to three-dimensional images. METHODS Personalized optical raytracing simulations were performed for 27 subjects, using subject-specific eye models based on corneal topography, biometry, and MRI. Light rays were traced through the eye for angles of 0°-85° with respect to the optical axis, in steps of 5°. These simulations provided a reference mapping between camera angles and retinal locations and were used to develop a mapping method without raytracing. The accuracy of this and earlier proposed methods was evaluated. Finally, the most accurate method was implemented in RayOcular, an image-based OPT planning system, and the fundus photography-based tumor contour was compared with MRI. RESULTS When a patient-specific second nodal point is taken as a reference to describe the retinal location, the camera, and retinal angles show a strong linear relation with a small variation between subjects. At a camera angle of 60°, for example, a corresponding retinal angle of 59.9° ± 0.4° (mean ± SD) was found. When this linear relation is used to predict the corresponding retinal location (without raytracing) of a camera angle of 40°, the mean (Euclidian distance) error in the retinal location was 0.02 mm (SD = 0.06 mm), which was significantly (p < 0.001) lower than earlier proposed methods including EYEPLAN 4.16 mm (SD = 0.25 mm), the Lamberth projection -0.12 mm (SD = 0.46 mm) or polar projection 0.26 mm (SD = 0.57 mm). When implemented in the fundus view of RayOcular, the median distance between contours based on MRI and fundus photography was 0.2 mm (IQR = 0.1-0.3 mm). CONCLUSIONS The second nodal point provides a patient-specific reference for an accurate mapping of fundus photographs to three-dimensional images with sub-millimeter errors.
Collapse
Affiliation(s)
- Corné Haasjes
- Department of OphthalmologyLeiden University Medical CenterLeidenThe Netherlands
- Department of RadiologyLeiden University Medical CenterLeidenThe Netherlands
- Department of Radiation OncologyLeiden University Medical CenterLeidenThe Netherlands
| | - T. H. Khanh Vu
- Department of OphthalmologyLeiden University Medical CenterLeidenThe Netherlands
| | - Jan‐Willem M. Beenakker
- Department of OphthalmologyLeiden University Medical CenterLeidenThe Netherlands
- Department of RadiologyLeiden University Medical CenterLeidenThe Netherlands
- Department of Radiation OncologyLeiden University Medical CenterLeidenThe Netherlands
| |
Collapse
|
2
|
Hrbacek J, Kacperek A, Beenakker JWM, Mortimer L, Denker A, Mazal A, Shih HA, Dendale R, Slopsema R, Heufelder J, Mishra KK. PTCOG Ocular Statement: Expert Summary of Current Practices and Future Developments in Ocular Proton Therapy. Int J Radiat Oncol Biol Phys 2024; 120:1307-1325. [PMID: 38971383 DOI: 10.1016/j.ijrobp.2024.06.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2023] [Revised: 05/08/2024] [Accepted: 06/18/2024] [Indexed: 07/08/2024]
Abstract
Although rare cancers, ocular tumors are a threat to vision, quality of life, and potentially life expectancy of a patient. Ocular proton therapy (OPT) is a powerful tool for successfully treating this disease. The Particle Therapy Co-Operative Ocular Group) formulated an Evidence and Expert-Based Executive Summary of Current Practices and Future Developments in OPT: comparative dosimetric and clinical analysis with the different OPT systems is essential to set up planning guidelines, implement best practices, and establish benchmarks for eye preservation, vision, and quality of life measures. Contemporary prospective trials in select subsets of patients (eg, tumors near the optic disc and/or macula) may allow for dosimetric and clinical analysis between different radiation modalities and beamline systems to evaluate differences in radiation delivery and penumbra, and resultant tumor control, normal tissue complication rates, and overall clinical cost-effectiveness. To date, the combination of multimodal imaging (fundus photography, ultrasound, etc), ophthalmologist assessment, and clip surgery with radiation planning have been keys to successful treatment. Increased use of three-dimensional imaging (computed tomography/magnetic resonance imaging) is anticipated although its spatial resolution might be a limiting factor (eg, detection of flat diffuse tumor parts). Commercially produced ocular treatment-planning systems are under development and their future use is expected to expand across OPT centers. Future continuity of OPT will depend on the following: (1) maintaining and upgrading existing older dedicated low-energy facilities, (2) maintaining shared, degraded beamlines at large proton therapy centers, and (3) developing adapted gantry beams of sufficient quality to maintain the clinical benefits of sharp beam conformity. Option (1) potentially offers the sharpest beams, minimizing impact on healthy tissues, whereas (2) and (3) potentially offer the advantage of substantial long-term technical support and development as well as the introduction of new approaches. Significant patient throughputs and close cooperation between medical physics, ophthalmology, and radiation therapy, underpinned by mutual understanding, is crucial for a successful OPT service.
Collapse
Affiliation(s)
- Jan Hrbacek
- Center for Proton Therapy, Paul Scherrer Institute, Villigen, Switzerland.
| | | | - Jan-Willem M Beenakker
- Department of Ophthalmology, Leiden University Medical Center, Leiden, Netherlands; Department of Radiology, C.J. Gorter MRI Center, Leiden University Medical Center, Leiden, Netherlands; Department of Radiation Oncology, Leiden University Medical Center, Leiden, Netherlands; HollandPTC, Delft, Netherlands
| | - Linda Mortimer
- Medical Physics Department, The Clatterbridge Cancer Centre NHS Foundation Trust, Birkenhead, United Kingdom
| | - Andrea Denker
- Helmholtz-Zentrum Berlin für Materialien und Energie, Proton Therapy (BE-APT), Berlin, Germany
| | - Alejandro Mazal
- Medical Physics Service, Centro de Protonterapia Quironsalud, Madrid, Spain
| | - Helen A Shih
- Harvard Medical School, Boston, Massachusetts; Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts
| | - Remi Dendale
- Institut Curie Protontherapy Center, Orsay, France
| | - Roelf Slopsema
- Department of Radiation Oncology, Emory Proton Therapy Center, Atlanta, Georgia
| | - Jens Heufelder
- Department of Ophthalmology, Charité - Universitätsmedizin Berlin, BerlinProtonen am HZB, Berlin, Germany
| | - Kavita K Mishra
- Proton Ocular Radiation Therapy Program, Department of Radiation Oncology, Osher Center for Integrative Health, Osher Foundation Endowed Chair in Clinical Programs in Integrative Health, University of California San Francisco, San Francisco, California
| |
Collapse
|
3
|
Björkman D, Via R, Lomax A, De Prado M, Baroni G, Weber DC, Hrbacek J. The effect of intra- and inter-fractional motion on target coverage and margins in proton therapy for uveal melanoma. Phys Med Biol 2024; 69:215038. [PMID: 39357536 DOI: 10.1088/1361-6560/ad8297] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2024] [Accepted: 10/02/2024] [Indexed: 10/04/2024]
Abstract
Introduction.This study aims to assess the effective lateral margin requirements for target coverage in ocular proton therapy (OPT), considering the unique challenges posed by eye motion and hypofractionation. It specifically addresses the previously unaccounted-for uncertainty contribution of intra-fractional motion, in conjunction with setup uncertainties, on dosimetric determination of lateral margin requirements.Method.The methodology integrates dose calculations from the in-house developed treatment planning system OCULARIS with measured intra-fractional motion, patient models from EyePlan and Monte Carlo (MC) sampling of setup uncertainties. The study is conducted on 16 uveal melanoma patients previously treated in the OPTIS2 treatment room at the Paul Scherrer Institute (PSI).Result.The retrospective simulation analysis highlights a significant impact of non-systematic factors on lateral margin requirements in OPT. Simulations indicate that reducing the 2.5 mm clinical lateral margin, represented by a 2.1 mm margin in this work, would have resulted in inadequate target coverage for two patients, revealing a greater impact of non-systematic factors on lateral margin requirements.Conclusions.This work characterizes intra-fractional motion in 16 OPT patients and identifies limitations of clinical margin selection protocols for OPT applications. A novel framework was introduced to assess margin sufficiency for target coverage. The findings suggest that prior research underestimated non-systematic factors and overestimated systematic contributions to lateral margin components. This re-evaluation highlights the critical need to prioritize the management of non-systematic uncertainty contributions in OPT.
Collapse
Affiliation(s)
- Daniel Björkman
- Center for Proton Therapy (CPT), Paul Scherrer Institute, Villigen, Switzerland
- Department of Physics, Eidgenössische Technische Hochschule (ETH), Zürich, Switzerland
| | - Riccardo Via
- Center for Proton Therapy (CPT), Paul Scherrer Institute, Villigen, Switzerland
| | - Antony Lomax
- Center for Proton Therapy (CPT), Paul Scherrer Institute, Villigen, Switzerland
- Department of Physics, Eidgenössische Technische Hochschule (ETH), Zürich, Switzerland
| | - Maria De Prado
- Center for Proton Therapy (CPT), Paul Scherrer Institute, Villigen, Switzerland
| | - Guido Baroni
- Department of Electronics Information and Bioengineering, Politecnico di Milano, Milano, Italy
| | - D C Weber
- Center for Proton Therapy (CPT), Paul Scherrer Institute, Villigen, Switzerland
- Department of Radiation Oncology, University Hospital of Zürich, Zurich, Switzerland
- Department of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
| | - Jan Hrbacek
- Center for Proton Therapy (CPT), Paul Scherrer Institute, Villigen, Switzerland
| |
Collapse
|
4
|
Klaassen L, Jaarsma-Coes MG, Marinkovic M, Luyten GPM, Rasch CRN, Ferreira TA, Beenakker JWM. Quantitative Perfusion-Weighted Magnetic Resonance Imaging in Uveal Melanoma. Invest Ophthalmol Vis Sci 2024; 65:17. [PMID: 39250118 PMCID: PMC11385876 DOI: 10.1167/iovs.65.11.17] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/10/2024] Open
Abstract
Purpose Perfusion-weighted imaging (PWI; magnetic resonance imaging [MRI]) has been shown to provide valuable biological tumor information in uveal melanoma (UM). Clinically used semiquantitative methods do not account for tumor pigmentation and eye movement. We hypothesize that a quantitative PWI method that incorporates these, provides a more accurate description of tumor perfusion than the current clinical method. The aim of this study was to test this in patients with UM before and after radiotherapy. Methods Perfusion-weighted 3T MRIs were retrospectively analyzed in 47 patients with UM before and after radiotherapy. Tofts pharmacokinetic modeling was performed to determine vascular permeability (Ktrans), extracellular extravascular space (ve), and reflux rate (kep). These were compared with semiquantitative clinical parameters including peak intensity and outflow percentage. Results The effect of tumor pigmentation on peak intensity and outflow percentage was statistically significant (P < 0.01) and relative peak intensity was significantly different between melanotic and amelanotic tumors (1.5 vs. 1.9, P < 0.01). Before radiotherapy, median tumor Ktrans was 0.63 min-1 (range = 0.06-1.42 min-1), median ve was 0.23 (range = 0.09-0.63), and median kep was 2.3 min-1 (range = 0.6-5.0 min-1). After radiotherapy, 85% showed a decrease in Ktrans and kep (P < 0.01). Changes in tumor pigmentation before and after radiotherapy were small and not significant (median increase in T1 of 33 ms, P = 0.55). Conclusions Quantitative PWI parameters decreased significantly after radiotherapy and can therefore can serve as an early biomarker for treatment response assessment. However, due to the nonsignificant changes in tumor pigmentation before and after radiotherapy, the current semiquantitative method appears to be sufficiently sensitive for detection of changes in tumor perfusion.
Collapse
Affiliation(s)
- Lisa Klaassen
- Leiden University Medical Center, Department of Ophthalmology, Leiden, The Netherlands
- Leiden University Medical Center, Department of Radiology, Leiden, The Netherlands
- Leiden University Medical Center, Department of Radiation Oncology, Leiden, The Netherlands
| | - Myriam G Jaarsma-Coes
- Leiden University Medical Center, Department of Ophthalmology, Leiden, The Netherlands
- Leiden University Medical Center, Department of Radiology, Leiden, The Netherlands
| | - Marina Marinkovic
- Leiden University Medical Center, Department of Ophthalmology, Leiden, The Netherlands
| | - Gregorius P M Luyten
- Leiden University Medical Center, Department of Ophthalmology, Leiden, The Netherlands
| | - Coen R N Rasch
- Leiden University Medical Center, Department of Radiation Oncology, Leiden, The Netherlands
- HollandPTC, Delft, The Netherlands
| | - Teresa A Ferreira
- Leiden University Medical Center, Department of Radiology, Leiden, The Netherlands
| | - Jan-Willem M Beenakker
- Leiden University Medical Center, Department of Ophthalmology, Leiden, The Netherlands
- Leiden University Medical Center, Department of Radiology, Leiden, The Netherlands
- Leiden University Medical Center, Department of Radiation Oncology, Leiden, The Netherlands
| |
Collapse
|
5
|
Klaassen L, Haasjes C, Hol M, Cambraia Lopes P, Spruijt K, van de Steeg-Henzen C, Vu K, Bakker P, Rasch C, Verbist B, Beenakker JW. Geometrical accuracy of magnetic resonance imaging for ocular proton therapy planning. Phys Imaging Radiat Oncol 2024; 31:100598. [PMID: 38993288 PMCID: PMC11234150 DOI: 10.1016/j.phro.2024.100598] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2024] [Revised: 05/31/2024] [Accepted: 06/05/2024] [Indexed: 07/13/2024] Open
Abstract
Background & purpose Magnetic resonance imaging (MRI) is increasingly used in treatment preparation of ocular proton therapy, but its spatial accuracy might be limited by geometric distortions due to susceptibility artefacts. A correct geometry of the MR images is paramount since it defines where the dose will be delivered. In this study, we assessed the geometrical accuracy of ocular MRI. Materials & methods A dedicated ocular 3 T MRI protocol, with localized shimming and increased gradients, was compared to computed tomography (CT) and X-ray images in a phantom and in 15 uveal melanoma patients. The MRI protocol contained three-dimensional T2-weighted and T1-weighted sequences with an isotropic reconstruction resolution of 0.3-0.4 mm. Tantalum clips were identified by three observers and clip-clip distances were compared between T2-weighted and T1-weighted MRI, CT and X-ray images for the phantom and between MRI and X-ray images for the patients. Results Interobserver variability was below 0.35 mm for the phantom and 0.30(T1)/0.61(T2) mm in patients. Mean absolute differences between MRI and reference were below 0.27 ± 0.16 mm and 0.32 ± 0.23 mm for the phantom and in patients, respectively. In patients, clip-clip distances were slightly larger on MRI than on X-ray images (mean difference T1: 0.11 ± 0.38 mm, T2: 0.10 ± 0.44 mm). Differences did not increase at larger distances and did not correlate to interobserver variability. Conclusions A dedicated ocular MRI protocol can produce images of the eye with a geometrical accuracy below half the MRI acquisition voxel (<0.4 mm). Therefore, these images can be used for ocular proton therapy planning, both in the current model-based workflow and in proposed three-dimensional MR-based workflows.
Collapse
Affiliation(s)
- Lisa Klaassen
- Leiden University Medical Center, Department of Ophthalmology, Leiden, the Netherlands
- Leiden University Medical Center, Department of Radiology, Leiden, the Netherlands
- Leiden University Medical Center, Department of Radiation Oncology, Leiden, the Netherlands
| | - Corné Haasjes
- Leiden University Medical Center, Department of Ophthalmology, Leiden, the Netherlands
- Leiden University Medical Center, Department of Radiology, Leiden, the Netherlands
- Leiden University Medical Center, Department of Radiation Oncology, Leiden, the Netherlands
| | - Martijn Hol
- Leiden University Medical Center, Department of Radiation Oncology, Leiden, the Netherlands
- HollandPTC, Delft, the Netherlands
| | | | | | - Christal van de Steeg-Henzen
- Leiden University Medical Center, Department of Radiology, Leiden, the Netherlands
- HollandPTC, Delft, the Netherlands
| | - Khanh Vu
- Leiden University Medical Center, Department of Ophthalmology, Leiden, the Netherlands
| | - Pauline Bakker
- Leiden University Medical Center, Department of Radiation Oncology, Leiden, the Netherlands
- HollandPTC, Delft, the Netherlands
| | - Coen Rasch
- Leiden University Medical Center, Department of Radiation Oncology, Leiden, the Netherlands
- HollandPTC, Delft, the Netherlands
| | - Berit Verbist
- Leiden University Medical Center, Department of Radiology, Leiden, the Netherlands
- HollandPTC, Delft, the Netherlands
| | - Jan-Willem Beenakker
- Leiden University Medical Center, Department of Ophthalmology, Leiden, the Netherlands
- Leiden University Medical Center, Department of Radiology, Leiden, the Netherlands
- Leiden University Medical Center, Department of Radiation Oncology, Leiden, the Netherlands
| |
Collapse
|
6
|
Wulff J, Koska B, Ahmad Khalil D, Richter R, Maximilian Bäcker C, Bäumer C, Foerster A, Bechrakis NE, Timmermann B. Uncertainties in ocular proton planning and their impact on required margins. Phys Med 2024; 121:103358. [PMID: 38643558 DOI: 10.1016/j.ejmp.2024.103358] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/04/2023] [Revised: 03/11/2024] [Accepted: 04/16/2024] [Indexed: 04/23/2024] Open
Abstract
PURPOSE To review required margins in ocular proton therapy (OPT) based on an uncertainty estimation and to compare them with widely used values. Further, uncertainties when using registered funduscopy images in the 3D model is investigated. METHODS An uncertainty budget in planning and delivery was defined to determine required aperture and range margins. Setup uncertainties were considered for a cohort of treated patients and tested in a worst-case estimation. Other uncertainties were based on a best-guess and knowledge of institutional specifics, e.g. range reproducibility. Margins for funduscopy registration were defined resulting from scaling, rotation and translation of the image. Image formation for a wide-field fundus camera was reviewed and compared to the projection employed in treatment planning systems. RESULTS Values for aperture and range with margins of 2.5 mm as reported in literature could be determined. Aperture margins appear appropriate for setup uncertainties below 0.5 mm, but depend on lateral penumbra. Range margins depend on depth and associated density uncertainty in tissue. Registration of funduscopy images may require margins of >2 mm, increasing towards the equator. Difference in the projection may lead to discrepancies of several mm. CONCLUSIONS The commonly used 2.5 mm aperture margin was validated as an appropriate choice, while range margins could be reduced for lower ranges. Margins may however not include uncertainties in contouring and possible microscopic spread. If a target base is contoured on registered funduscopy images care must be taken as they are subject to larger uncertainties. Multimodal imaging approach in OPT remains advisable.
Collapse
Affiliation(s)
- Jörg Wulff
- West German Proton Therapy Centre Essen (WPE), Essen, Germany; University Hospital Essen, Essen, Germany; West German Cancer Centre (WTZ), Essen, Germany.
| | - Benjamin Koska
- West German Proton Therapy Centre Essen (WPE), Essen, Germany; University Hospital Essen, Essen, Germany; West German Cancer Centre (WTZ), Essen, Germany
| | - Dalia Ahmad Khalil
- West German Proton Therapy Centre Essen (WPE), Essen, Germany; University Hospital Essen, Essen, Germany; West German Cancer Centre (WTZ), Essen, Germany; Department of Particle Therapy, Essen, Germany
| | - Ronald Richter
- West German Proton Therapy Centre Essen (WPE), Essen, Germany; University Hospital Essen, Essen, Germany; West German Cancer Centre (WTZ), Essen, Germany; Department of Particle Therapy, Essen, Germany
| | - Claus Maximilian Bäcker
- West German Proton Therapy Centre Essen (WPE), Essen, Germany; University Hospital Essen, Essen, Germany; West German Cancer Centre (WTZ), Essen, Germany
| | - Christian Bäumer
- West German Proton Therapy Centre Essen (WPE), Essen, Germany; University Hospital Essen, Essen, Germany; West German Cancer Centre (WTZ), Essen, Germany; German Cancer Consortium (DKTK), Essen, Germany; Department of Physics, TU Dortmund University, Dortmund, Germany
| | - Andreas Foerster
- University Hospital Essen, Essen, Germany; Department of Ophthalmology, University Hospital Essen, Essen, Germany
| | - Nikolaos E Bechrakis
- University Hospital Essen, Essen, Germany; West German Cancer Centre (WTZ), Essen, Germany; Department of Ophthalmology, University Hospital Essen, Essen, Germany
| | - Beate Timmermann
- West German Proton Therapy Centre Essen (WPE), Essen, Germany; University Hospital Essen, Essen, Germany; West German Cancer Centre (WTZ), Essen, Germany; Department of Particle Therapy, Essen, Germany; German Cancer Consortium (DKTK), Essen, Germany
| |
Collapse
|
7
|
Lim JZ, Gokul A, Misra SL, Pan X, Charlton A, McGhee CNJ. An optimized 3T MRI scan protocol to assess iris melanoma with subsequent histopathological verification - A prospective study. Asia Pac J Ophthalmol (Phila) 2024; 13:100047. [PMID: 38417788 DOI: 10.1016/j.apjo.2024.100047] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2023] [Revised: 02/02/2024] [Accepted: 02/09/2024] [Indexed: 03/01/2024] Open
Abstract
INTRODUCTION Magnetic resonance imaging (MRI) has demonstrated high levels of tissue contrast, accuracy and reproducibility in evaluating posterior uveal melanoma. Owing to smaller size, the role of MRI in detecting and characterising iris melanoma has not yet been explored. AIMS To develop a protocol to image iris melanoma and describe the MRI characteristics of histopathological-confirmed iris melanoma. MATERIALS AND METHODS An optimised MRI protocol, using a 3T MRI scanner and a 32-channel head coil, was developed to image iris tumours. A prospective, single-centre, 12-month study was conducted on all patients with lesions suspicious for iris melanoma. All patients were offered an MRI scan in addition to the standardised clinical procedures. Image quality comparison was made with existing clinical investigations. Iris melanoma characteristics on MRI are described. RESULTS A successful optimised MRI scan protocol was developed that was able to detect and characterise iris melanoma. One normal participant and five patients with subsequent histopathological-confirmed iris melanoma (n = 6) were recruited. Four patients completed the full MRI sequence. All iris melanoma were detected on at least one T1- or T2-weighted images. When compared to the vitreous, all iris melanomas demonstrated hyper-intensity on T1-weighted images and hypo-intensity on T2-weighted images. On T1-mapping, T1-values of iris melanoma demonstrated an inverse relationship with the degree of tumour pigmentation. CONCLUSIONS This study highlights an optimised, easily reproducible MRI scan protocol to image iris melanoma. Numerous MR imaging characteristics of iris melanoma are reported for the first time and a potential non-invasive tumour biomarker is described.
Collapse
Affiliation(s)
- Joevy Z Lim
- Department of Ophthalmology, New Zealand Eye Centre, University of Auckland, New Zealand; Department of Ophthalmology, Te Whatu Ora - Health New Zealand Auckland, New Zealand
| | - Akilesh Gokul
- Department of Ophthalmology, New Zealand Eye Centre, University of Auckland, New Zealand
| | - Stuti L Misra
- Department of Ophthalmology, New Zealand Eye Centre, University of Auckland, New Zealand
| | - Xingzheng Pan
- Department of Physiology, School of Medical Science, New Zealand Eye Centre, University of Auckland, New Zealand
| | - Amanda Charlton
- Department of Histopathology, Te Whatu Ora - Health New Zealand Auckland, New Zealand
| | - Charles N J McGhee
- Department of Ophthalmology, New Zealand Eye Centre, University of Auckland, New Zealand; Department of Ophthalmology, Te Whatu Ora - Health New Zealand Auckland, New Zealand.
| |
Collapse
|
8
|
Pors LJ, Haasjes C, van Vught L, Hoes NP, Luyten GPM, van Rijn GA, Vu THK, Rasch CRN, Horeweg N, Beenakker JWM. Correction Method for Optical Scaling of Fundoscopy Images: Development, Validation, and First Implementation. Invest Ophthalmol Vis Sci 2024; 65:43. [PMID: 38271188 PMCID: PMC10829800 DOI: 10.1167/iovs.65.1.43] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2023] [Accepted: 12/28/2023] [Indexed: 01/27/2024] Open
Abstract
Purpose Although fundus photography is extensively used in ophthalmology, refraction prevents accurate distance measurement on fundus images, as the resulting scaling differs between subjects due to varying ocular anatomy. We propose a PARaxial Optical fundus Scaling (PAROS) method to correct for this variation using commonly available clinical data. Methods The complete optics of the eye and fundus camera were modeled using ray transfer matrix formalism to obtain fundus image magnification. The subject's ocular geometry was personalized using biometry, spherical equivalent of refraction (RSE), keratometry, and/or corneal topography data. The PAROS method was validated using 41 different eye phantoms and subsequently evaluated in 44 healthy phakic subjects (of whom 11 had phakic intraocular lenses [pIOLs]), 29 pseudophakic subjects, and 21 patients with uveal melanoma. Results Validation of the PAROS method showed small differences between model and actual image magnification (maximum 3.3%). Relative to the average eye, large differences in fundus magnification were observed, ranging from 0.79 to 1.48. Magnification was strongly inversely related to RSE (R2 = 0.67). In phakic subjects, magnification was directly proportional to axial length (R2 = 0.34). The inverse relation was seen in pIOL (R2 = 0.79) and pseudophakic (R2 = 0.12) subjects. RSE was a strong contributor to magnification differences (1%-83%). As this effect is not considered in the commonly used Bennett-Littmann method, statistically significant differences up to 40% (mean absolute 9%) were observed compared to the PAROS method (P < 0.001). Conclusions The significant differences in fundus image scaling observed among subjects can be accurately accounted for with the PAROS method, enabling more accurate quantitative assessment of fundus photography.
Collapse
Affiliation(s)
- Lennart J. Pors
- Department of Radiation Oncology, Leiden University Medical Center, Leiden, the Netherlands
- Department of Ophthalmology, Leiden University Medical Center, Leiden, the Netherlands
| | - Corné Haasjes
- Department of Radiation Oncology, Leiden University Medical Center, Leiden, the Netherlands
- Department of Ophthalmology, Leiden University Medical Center, Leiden, the Netherlands
- Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands
| | - Luc van Vught
- Department of Ophthalmology, Leiden University Medical Center, Leiden, the Netherlands
- Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands
| | - Noor P. Hoes
- Department of Ophthalmology, Leiden University Medical Center, Leiden, the Netherlands
| | | | - Gwyneth A. van Rijn
- Department of Ophthalmology, Amsterdam University Medical Center, Amsterdam, the Netherlands
- Department of Ophthalmology, Northwest Clinics, Alkmaar, the Netherlands
| | - T. H. Khanh Vu
- Department of Ophthalmology, Leiden University Medical Center, Leiden, the Netherlands
| | - Coen R. N. Rasch
- Department of Radiation Oncology, Leiden University Medical Center, Leiden, the Netherlands
| | - Nanda Horeweg
- Department of Radiation Oncology, Leiden University Medical Center, Leiden, the Netherlands
- Department of Ophthalmology, Leiden University Medical Center, Leiden, the Netherlands
| | - Jan-Willem M. Beenakker
- Department of Radiation Oncology, Leiden University Medical Center, Leiden, the Netherlands
- Department of Ophthalmology, Leiden University Medical Center, Leiden, the Netherlands
- Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands
| |
Collapse
|
9
|
Jaarsma-Coes MG, Klaassen L, Verbist BM, Vu TK, Klaver YL, Rodrigues MF, Nabarro C, Luyten GP, Rasch CR, van Herk M, Beenakker JWM. Inter-Observer Variability in MR-Based Target Volume Delineation of Uveal Melanoma. Adv Radiat Oncol 2022; 8:101149. [PMID: 36691449 PMCID: PMC9860418 DOI: 10.1016/j.adro.2022.101149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2022] [Accepted: 12/14/2022] [Indexed: 12/26/2022] Open
Abstract
Purpose Several efforts are being undertaken toward MRI-based treatment planning for ocular proton therapy for uveal melanoma (UM). The interobserver variability of the gross target volume (GTV) on magnetic resonance imaging (MRI) is one of the important parameters to design safety margins for a reliable treatment. Therefore, this study assessed the interobserver variation in GTV delineation of UM on MRI. Methods and Materials Six observers delineated the GTV in 10 different patients using the Big Brother contouring software. Patients were scanned at 3T MRI with a surface coil, and tumors were delineated separately on contrast enhanced 3DT1 (T1gd) and 3DT2-weighted scans with an isotropic acquisition resolution of 0.8 mm. Volume difference and overall local variation (median standard deviation of the distance between the delineated contours and the median contour) were analyzed for each GTV. Additionally, the local variation was analyzed for 4 interfaces: sclera, vitreous, retinal detachment, and tumor-choroid interface. Results The average GTV was significantly larger on T1gd (0.57cm3) compared with T2 (0.51cm3, P = .01). A not significant higher interobserver variation was found on T1gd (0.41 mm) compared with T2 (0.35 mm). The largest variations were found at the tumor-choroid interface due to peritumoral enhancement (T1gd, 0.62 mm; T2, 0.52 mm). As a result, a larger part of this tumor-choroid interface appeared to be included on T1gd-based GTVs compared with T2, explaining the smaller volumes on T2. Conclusions The interobserver variation of 0.4 mm on MRI are low with respect to the voxel size of 0.8 mm, enabling small treatment margins. We recommend delineation based on the T1gd-weighted scans, as choroidal tumor extensions might be missed.
Collapse
Affiliation(s)
- Myriam G. Jaarsma-Coes
- Leiden University Medical Center, Ophthalmology, Leiden, Netherlands,Leiden University Medical Center, Radiology, Leiden, Netherlands
| | - Lisa Klaassen
- Leiden University Medical Center, Ophthalmology, Leiden, Netherlands,Leiden University Medical Center, Radiology, Leiden, Netherlands
| | - Berit M. Verbist
- Leiden University Medical Center, Radiology, Leiden, Netherlands
| | - T.H. Khanh Vu
- Leiden University Medical Center, Ophthalmology, Leiden, Netherlands
| | - Yvonne L.B. Klaver
- HollandPTC, Radiation oncology, Delft, Netherlands,Leiden University Medical Center, Radiation Oncology, Leiden, Netherlands
| | - Myra F. Rodrigues
- HollandPTC, Radiation oncology, Delft, Netherlands,Leiden University Medical Center, Radiation Oncology, Leiden, Netherlands
| | - Claire Nabarro
- Leiden University Medical Center, Radiology, Leiden, Netherlands
| | | | - Coen R.N. Rasch
- HollandPTC, Radiation oncology, Delft, Netherlands,Leiden University Medical Center, Radiation Oncology, Leiden, Netherlands
| | - Marcel van Herk
- Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom
| | - Jan-Willem M. Beenakker
- Leiden University Medical Center, Ophthalmology, Leiden, Netherlands,Leiden University Medical Center, Radiology, Leiden, Netherlands,Leiden University Medical Center, Radiation Oncology, Leiden, Netherlands,Corresponding author: Jan-Willem M. Beenakker
| |
Collapse
|
10
|
Beenakker JWM, Rasch CRN. Letter to the Editor of Radiotherapy and Oncology regarding the paper titled "MRI and FUNDUS image fusion for improved ocular biometry in Ocular Proton Therapy" by Via et al. Radiother Oncol 2022; 176:251. [PMID: 35988772 DOI: 10.1016/j.radonc.2022.08.018] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2022] [Accepted: 08/15/2022] [Indexed: 12/14/2022]
Affiliation(s)
- Jan-Willem M Beenakker
- Department of Radiation Oncology, Leiden University Medical Center, 2333ZA Leiden, The Netherlands; Department of Radiology, Leiden University Medical Center, 2333ZA Leiden, The Netherlands; Department of Ophthalmology, Leiden University Medical Center, 2333ZA Leiden, The Netherlands.
| | - Coen R N Rasch
- Department of Radiation Oncology, Leiden University Medical Center, 2333ZA Leiden, The Netherlands
| |
Collapse
|
11
|
Via R, Fattori G, Pica A, Paganelli C, Lomax A, Schalenbourg A, Weber DC, Baroni G, Hrbacek J. Response to "Letter to the Editor of Radiotherapy and Oncology regarding the paper titled "MRI and FUNDUS image fusion for improved ocular biometry in Ocular Proton Therapy" by Via et al.". Radiother Oncol 2022; 176:252. [PMID: 35988774 DOI: 10.1016/j.radonc.2022.08.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2022] [Accepted: 08/15/2022] [Indexed: 12/14/2022]
Affiliation(s)
- Riccardo Via
- Paul Scherrer Institut (PSI), Center for Proton Therapy, 5232 Villigen PSI, Switzerland.
| | - Giovanni Fattori
- Paul Scherrer Institut (PSI), Center for Proton Therapy, 5232 Villigen PSI, Switzerland
| | - Alessia Pica
- Paul Scherrer Institut (PSI), Center for Proton Therapy, 5232 Villigen PSI, Switzerland
| | - Chiara Paganelli
- Dipartimento di Elettronica Informazione e Bioingegneria, Politecnico di Milano, Milano 20133, Italy
| | - Antony Lomax
- Paul Scherrer Institut (PSI), Center for Proton Therapy, 5232 Villigen PSI, Switzerland
| | - Ann Schalenbourg
- Department of Ophthalmology, University of Lausanne, Jules-Gonin Eye Hospital, FAA, Lausanne, Switzerland
| | - Damien Charles Weber
- Paul Scherrer Institut (PSI), Center for Proton Therapy, 5232 Villigen PSI, Switzerland; Department of Radiation Oncology, University Hospital Zurich, Rämistrasse 100, 8091 Zurich, Switzerland; Department of Radiation Oncology, University Hospital Bern, Freiburgstrasse 18, 3010 Bern, Switzerland
| | - Guido Baroni
- Dipartimento di Elettronica Informazione e Bioingegneria, Politecnico di Milano, Milano 20133, Italy
| | - Jan Hrbacek
- Paul Scherrer Institut (PSI), Center for Proton Therapy, 5232 Villigen PSI, Switzerland
| |
Collapse
|
12
|
Klaassen L, Jaarsma-Coes MG, Verbist BM, Vu TK, Marinkovic M, Rasch CR, Luyten GP, Beenakker JWM. Automatic Three-Dimensional Magnetic Resonance-based measurements of tumour prominence and basal diameter for treatment planning of uveal melanoma. Phys Imaging Radiat Oncol 2022; 24:102-110. [PMID: 36386446 PMCID: PMC9649381 DOI: 10.1016/j.phro.2022.11.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2022] [Revised: 10/31/2022] [Accepted: 11/01/2022] [Indexed: 11/07/2022] Open
Abstract
Background and Purpose Three-dimensional (3D) Magnetic Resonance Imaging (MRI) is increasingly used to complement conventional two-dimensional ultrasound in the assessment of tumour dimension measurement of uveal melanoma. However, the lack of definitions of the 3D measurements of these tumour dimensions hinders further adaptation of MRI in ocular radiotherapy planning. In this study, we composed 3D MR-based definitions of tumour prominence and basal diameter and compared them to conventional ultrasound. Materials and methods Tumours were delineated on 3DT2 and contrast-enhanced 3DT1 (T1gd) MRI for 25 patients. 3D definitions of tumour prominence and diameter were composed and evaluated automatically on the T1gd and T2 contours. Automatic T1gd measurements were compared to manual MRI measurements, to automatic T2 measurements and to manual ultrasound measurements. Results Prominence measurements were similar for all modalities (median absolute difference 0.3 mm). Automatic T1gd diameter measurements were generally larger than manual MRI, automatic T2 and manual ultrasound measurements (median absolute differences of 0.5, 1.6 and 1.1 mm respectively), mainly due to difficulty defining the axis of the largest diameter. Largest differences between ultrasound and MRI for both prominence and diameter were found in anteriorly located tumours (up to 1.6 and 4.5 mm respectively), for which the tumour extent could not entirely be visualized with ultrasound. Conclusions The proposed 3D definitions for tumour prominence and diameter agreed well with ultrasound measurements for tumours for which the extent was visible on ultrasound. 3D MRI measurements generally provided larger diameter measurements than ultrasound. In anteriorly located tumours, the MRI measurements were considered more accurate than conventional ultrasound.
Collapse
Affiliation(s)
- Lisa Klaassen
- Leiden University Medical Center, Department of Ophthalmology, PO Box 9600, 2300 RC Leiden, the Netherlands
- Leiden University Medical Center, Department of Radiology, PO Box 9600, 2300 RC Leiden, the Netherlands
- Leiden University Medical Center, Department of Radiation Oncology, PO Box 9600, 2300 RC Leiden, the Netherlands
| | - Myriam G. Jaarsma-Coes
- Leiden University Medical Center, Department of Ophthalmology, PO Box 9600, 2300 RC Leiden, the Netherlands
- Leiden University Medical Center, Department of Radiology, PO Box 9600, 2300 RC Leiden, the Netherlands
| | - Berit M. Verbist
- Leiden University Medical Center, Department of Radiology, PO Box 9600, 2300 RC Leiden, the Netherlands
- Holland Particle Therapy Center, PO Box 110, 2600 AC Delft, the Netherlands
| | - T.H. Khanh Vu
- Leiden University Medical Center, Department of Ophthalmology, PO Box 9600, 2300 RC Leiden, the Netherlands
| | - Marina Marinkovic
- Leiden University Medical Center, Department of Ophthalmology, PO Box 9600, 2300 RC Leiden, the Netherlands
| | - Coen R.N. Rasch
- Leiden University Medical Center, Department of Radiation Oncology, PO Box 9600, 2300 RC Leiden, the Netherlands
- Holland Particle Therapy Center, PO Box 110, 2600 AC Delft, the Netherlands
| | - Gregorius P.M. Luyten
- Leiden University Medical Center, Department of Ophthalmology, PO Box 9600, 2300 RC Leiden, the Netherlands
| | - Jan-Willem M. Beenakker
- Leiden University Medical Center, Department of Ophthalmology, PO Box 9600, 2300 RC Leiden, the Netherlands
- Leiden University Medical Center, Department of Radiology, PO Box 9600, 2300 RC Leiden, the Netherlands
- Leiden University Medical Center, Department of Radiation Oncology, PO Box 9600, 2300 RC Leiden, the Netherlands
| |
Collapse
|